Skip to main navigation Skip to search Skip to main content

Hippocampal and amygdala subfield volumes in obsessive-compulsive disorder by medication status

  • Ziphozihle Ntwatwa
  • , Christine Lochner
  • , Annerine Roos
  • , Tatum Sevenoaks
  • , Jack van Honk
  • , Marcelo C. Batistuzzo
  • , Sunah Choi
  • , Marcelo Q. Hoexter
  • , Minah Kim
  • , Jun Soo Kwon
  • , David Mataix-Cols
  • , José M. Menchón
  • , Euripedes C. Miguel
  • , Takashi Nakamae
  • , Carles Soriano-Mas
  • , Dick J. Veltman
  • , Nynke A. Groenewold
  • , Odile A. van den Heuvel
  • , Dan J. Stein
  • , Jonathan Ipser
  • University of Cape Town
  • University of Stellenbosch
  • Universidade de São Paulo
  • Pontifical Catholic University
  • Seoul National University College of Medicine
  • Seoul National University College of Natural Sciences
  • Karolinska Institutet
  • Stockholm Health Care Services
  • Lund University
  • Bellvitge University Hospital
  • Kyoto Prefectural University of Medicine
  • Amsterdam Neuroscience
  • Amsterdam University Medical Center

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

BACKGROUND: Although it has been suggested that the hippocampus and amygdala (HA) are involved in the neurobiology of obsessive-compulsive disorder (OCD), volumetric findings have been inconsistent, and little work has been undertaken on the volumetry of the heterogeneous anatomic units of HA, with their specific functions and cytoarchitecture, in OCD. We sought to explore potential sources of heterogeneity in brain volumes by performing a separate analysis for people with and without psychotropic medication use, as well as the association of subfield volumes with OCD symptom severity. METHODS: We segmented T1-weighted images from people with OCD and healthy controls in the OCD Brain Imaging Consortium to produce 12 hippocampal subfields and 9 amygdala subfields using Free-Surfer 6.0. We assessed between-group differences in subfield volume using a mixed-effects model adjusted for age and quadratic effects of age, sex, site, and whole HA volume. We also performed subgroup analyses to examine subfield volume in relation to comorbid anxiety and depression, medication status, and symptom severity. We corrected all analyses for multiple comparisons using the false discovery rate (FDR). RESULTS: We included images from 381 people with OCD and 338 healthy controls. These groups did not significantly differ in HA subfield volumes. However, medicated people with OCD had significantly smaller volumes in the hippocampal dentate gyrus (pFDR = 0.04, d = -0.26) and molecular layer (pFDR = 0.04, d = -0.29), and larger volumes in the lateral (pFDR = 0.049, d = 0.23) and basal (pFDR = 0.049, d = 0.25) amygdala subfields, than healthy controls. Unmedicated people with OCD had significantly smaller volumes in the hippocampal cornu ammonis sector 1 (pFDR = 0.02, d = -0.28) than controls. We did not detect associations between any subfield volume and OCD severity. LIMITATIONS: We used cross-sectional data, which limits the interpretation of our analysis. CONCLUSION: Differences in HA subfields between people with OCD and healthy controls are dependent on medication status, in line with previous work on other brain volumetric alterations in OCD. This emphasizes the importance of considering psychotropic medication in neuroimaging studies of OCD.

Original languageEnglish
Pages (from-to)E170-E180
Number of pages11
JournalJournal of psychiatry & neuroscience : JPN
Volume50
Issue number3
DOIs
Publication statusPublished - 27 May 2025

Bibliographical note

Publisher Copyright:
© 2025 CMA Impact Inc.

Funding

Ziphozihle Ntwatwa was partially funded by a grant from the Carnegie Corporation of New York. This work was supported in part by the Oppenheimer Memorial Trust. Other sources of support include the National Research Foundation of South Africa to Christine Lochner; Dutch Organization for Scientific Research (nos. 912-02-050, 907-00-012, 940-37-018, and 916.86.038); Carlos III Health Institute (nos. PI09/01331, PI10/01753, PI10/01003, CP10/00604, and CIBER-CB06/03/0034); Agency for Administration of University and Research (no. 2009SGR1554); a Miguel Servet contract from the Carlos III Health Institute (no. CP10/00604) to Carles Soriano-Mas; a Wellcome Trust project grant (no. 064846) to David Mataix-Cols; a grant from the Foundation for the Support of Research in the State of São Paulo to Euripedes Miguel (FAPESP; no. 2005/55628-8); a FAPESP scholarship to Marcelo Hoexter (2005/04206-6); Brain Science Convergence Research Program (RS-2023-00266120) and the Basic Research Program of the Korea Brain Research Institute (no. 25-BR-05-05) to Minah Kim, funded by the Ministry of Science and Information and Communication Technologies; and a National Research Foundation of Korea grant funded by the Ministry of Education, Science, and Technology (no. 2012-0005150).

FundersFunder number
Ministry of Science and ICT, South Korea
National Research Foundation of Korea
Ernest Oppenheimer Memorial Trust
Carnegie Corporation of New York
Fundação de Amparo à Pesquisa do Estado de São Paulo2005/04206-6, 2005/55628-8
Nederlandse Organisatie voor Wetenschappelijk Onderzoek940-37-018, 912-02-050, 916.86.038, 907-00-012
Brain Science Convergence Research ProgramRS-2023-00266120
Instituto de Salud Carlos IIIPI10/01003, PI09/01331, PI10/01753, CIBER-CB06/03/0034, CP10/00604
Agency for Administration of University and Research2009SGR1554
Korea Brain Research Institute25-BR-05-05
Wellcome Trust064846
Ministry of Education, Science and Technology2012-0005150

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Fingerprint

    Dive into the research topics of 'Hippocampal and amygdala subfield volumes in obsessive-compulsive disorder by medication status'. Together they form a unique fingerprint.

    Cite this